Methods of treating cancer using interleukin-12p40 variants having improved stability
US9029330B2 · kind B2 · utility
6Cited by
55References
26Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 23, 2012 |
| Grant date | May 12, 2015 |
| Priority date | — |
| Expiry date | Jul 11, 2032 |
Classification
- Technology area (CPC H)Electricity
- CPC primaryH04L41/5019
- WIPO fieldAudio-visual technology
- WIPO sectorElectrical engineering
Abstract
Modified interleukin-12 (IL-12) p40 polypeptides are disclosed. The modified polypeptides have alterations in the IL-12p40 subunit to eliminate the protease site between positions Lys260 and Arg261. The modified IL-12p40 polypeptides according to the invention have improved stability compared to wild-type mature human IL-12p40 polypeptides.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.